Literature DB >> 23090528

Perinatal outcomes in Hispanic and non-Hispanic white women with mild gestational diabetes.

Erica K Berggren1, Lisa Mele, Mark B Landon, Catherine Y Spong, Susan M Ramin, Brian Casey, Ronald J Wapner, Michael W Varner, Dwight J Rouse, Anthony Sciscione, Patrick Catalano, Margaret Harper, George Saade, Steve N Caritis, Yoram Sorokin, Alan M Peaceman, Jorge E Tolosa.   

Abstract

OBJECTIVE: To compare perinatal outcomes between self-identified Hispanic and non-Hispanic white women with mild gestational diabetes mellitus (GDM) or glucose intolerance.
METHODS: In a secondary analysis of a mild GDM treatment trial, we compared perinatal outcomes by race and ethnicity for 767 women with glucose intolerance (abnormal 50-g 1-hour screen, normal 100-g 3-hour oral glucose tolerance test), 371 women with mild GDM assigned to usual prenatal care, and 397 women with mild GDM assigned to treatment. Outcomes included: composite adverse perinatal outcome (neonatal death, hypoglycemia, hyperbilirubinemia, hyperinsulinemia, stillbirth, birth trauma), gestational age at delivery, birth weight, and hypertensive disorders of pregnancy. Adjusted regression models included: 100-g 3-hour oral glucose tolerance test results, parity, gestational age, body mass index, maternal age at enrollment, and current tobacco use.
RESULTS: The sample of 1,535 women was 68.3% Hispanic and 31.7% non-Hispanic white. Among women with glucose intolerance, Hispanic women had more frequent composite outcome (37% compared with 27%, adjusted odds ratio [OR] 1.62, 95% confidence interval [CI] 1.10-2.37) with more neonatal elevated C-cord peptide (19% compared with 13%, adjusted OR 1.79, 95% CI 1.04-3.08) and neonatal hypoglycemia (21% compared with 13%, adjusted OR 2.04, 95% CI 1.18-3.53). Among women with untreated mild GDM, outcomes were similar by race and ethnicity. Among Hispanic women with treated mild GDM, composite outcome was similar to non-Hispanic white women (35% compared with 25%, adjusted OR 1.62, 95% CI 0.92-2.86), but Hispanic neonates had more frequent hyperinsulinemia (21% compared with 10%, adjusted OR 2.96, 95% CI 1.33-6.60).
CONCLUSION: Individual components of some neonatal outcomes were more frequent in Hispanic neonates, but most perinatal outcomes were similar between Hispanic and non-Hispanic ethnic groups. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2012        PMID: 23090528      PMCID: PMC3531801          DOI: 10.1097/aog.0b013e31827049a5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  23 in total

1.  1994-1996 U.S. singleton birth weight percentiles for gestational age by race, Hispanic origin, and gender.

Authors:  G R Alexander; M D Kogan; J H Himes
Journal:  Matern Child Health J       Date:  1999-12

2.  National Diabetes Data Group vs Carpenter-Coustan criteria to diagnose gestational diabetes.

Authors:  Erica K Berggren; Kim A Boggess; Alison M Stuebe; Michele Jonsson Funk
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 8.661

3.  Perinatal outcomes in patients with gestational diabetes mellitus by race/ethnicity.

Authors:  Tania F Esakoff; Aaron B Caughey; Ingrid Block-Kurbisch; Maribeth Inturrisi; Yvonne W Cheng
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07-20

4.  Racial disparities in perinatal outcomes among women with gestational diabetes.

Authors:  Erica K Berggren; Kim A Boggess; Michele Jonsson Funk; Alison M Stuebe
Journal:  J Womens Health (Larchmt)       Date:  2012-01-04       Impact factor: 2.681

5.  Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.

Authors:  Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson
Journal:  N Engl J Med       Date:  2005-06-12       Impact factor: 91.245

6.  Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program.

Authors:  Dana Dabelea; Janet K Snell-Bergeon; Cynthia L Hartsfield; Kimberly J Bischoff; Richard F Hamman; Robert S McDuffie
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

7.  Gestational diabetes: the consequences of not treating.

Authors:  Oded Langer; Yariv Yogev; Orli Most; Elly M J Xenakis
Journal:  Am J Obstet Gynecol       Date:  2005-04       Impact factor: 8.661

8.  Trends and racial/ethnic disparities in gestational diabetes among pregnant women in New York City, 1990-2001.

Authors:  Lorna E Thorpe; Diana Berger; Jennifer A Ellis; Vani R Bettegowda; Gina Brown; Thomas Matte; Mary Bassett; Thomas R Frieden
Journal:  Am J Public Health       Date:  2005-07-28       Impact factor: 9.308

9.  Fetal and maternal outcomes in Indo-Asian compared to caucasian women with diabetes in pregnancy.

Authors:  F P Dunne; P A Brydon; M Proffitt; T Smith; H Gee; R L Holder
Journal:  QJM       Date:  2000-12

10.  Prevalence of gestational diabetes mellitus detected by the national diabetes data group or the carpenter and coustan plasma glucose thresholds.

Authors:  Assiamira Ferrara; Monique M Hedderson; Charles P Quesenberry; Joseph V Selby
Journal:  Diabetes Care       Date:  2002-09       Impact factor: 19.112

View more
  3 in total

Review 1.  Lifestyle interventions for the treatment of women with gestational diabetes.

Authors:  Julie Brown; Nisreen A Alwan; Jane West; Stephen Brown; Christopher Jd McKinlay; Diane Farrar; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2017-05-04

2.  The Effect of Mild Gestational Diabetes Mellitus Treatment on Adverse Pregnancy Outcomes: A Systemic Review and Meta-Analysis.

Authors:  Samira Behboudi-Gandevani; Razieh Bidhendi-Yarandi; Mohammad Hossein Panahi; Mojtaba Vaismoradi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-26       Impact factor: 5.555

3.  Maternal mortality in Spain and its association with country of origin: cross-sectional study during the period 1999-2015.

Authors:  V Blagoeva Atanasova; J Arevalo-Serrano; E Antolin Alvarado; Santiago García-Tizón Larroca
Journal:  BMC Public Health       Date:  2018-10-11       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.